GlassScriptPhysician profile
Rakesh Waghray
NPI 1124059969
$977.53
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $132 · 2021: $432 · 2022: $47.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $241.72 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.60 | 2019-2020 | |
| Insmed, INC. | $132.34 | 2019-2022 | |
| Abbott Laboratories | $122.40 | 2021 | |
| Edwards Lifesciences Corporation | $98.94 | 2021 | |
| Gilead Sciences, INC. | $96.26 | 2019 | |
| Glaxosmithkline, LLC. | $65.81 | 2019-2021 | |
| Grifols USA, LLC | $40.51 | 2019-2020 | |
| Electromed, INC. | $25.88 | 2021 | |
| Mylan Specialty L.P. | $18.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Waghray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.